Top Markets
Coin of the day
Golden Biotechnology Corporation Golden Biotechnology Corporation

Golden Biotechnology Corporation

4132
Classement en actions #29677
Golden Biotechnology Corporation, founded in 2002 and based in New Taipei City,... Golden Biotechnology Corporation, founded in 2002 and based in New Taipei City, Taiwan, is engaged in both pharmaceutical drug discovery and the production of health-enhancing dietary supplements. The company operates internationally, serving markets in Taiwan, the United States, Japan, China, Korea, and Singapore. Its varied product line includes several health supplements: Liverty, formulated to support liver function and help alleviate fatigue. Rasle, which serves as an adjunctive therapy for autoimmune conditions. ZSAINO, a nutritional product designed to aid recovery from illness and boost general well-being. UMOOZE, a specialized herbal blend targeting optimal health for men. Furthermore, Golden Biotechnology is developing Antroquinonol, an anticancer molecule. This compound is currently utilized in the treatment of severe conditions such as pancreatic cancer, acute myeloid leukemia, and hepatocellular carcinoma, in addition to addressing hypercholesterolemia and hyperlipidemia.
Prix de l'action
$0.11034263
Dernière synchronisation: 2026-04-09
Capitalisation boursière
$20.11M
Changement (1 jour)
-31.83%
Changement (1 an)
-73.09%
Pays
TW
Échange Golden Biotechnology Corporation (4132)

Catégorie

Bénéfices pour Golden Biotechnology Corporation (4132)
Bénéfices en 2026 TTM : 0
Selon les derniers rapports financiers de Golden Biotechnology Corporation, les bénéfices actuels de l'entreprise sont de 0. En 2026, l'entreprise a réalisé un bénéfice de 0, égal à celui de 2026 qui était de 0. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Golden Biotechnology Corporation de 2026 à 2026
Bénéfices à la fin de chaque année
Année Bénéfices Changez
Pas assez de données pour les dates fournies.
Bénéfices des entreprises similaires ou concurrentes